$6.53
2.35% yesterday
Nasdaq, Aug 12, 10:00 pm CET

Champions Oncology, Inc. Stock price

$6.53
-1.44 18.07% 1M
-4.46 40.58% 6M
-2.04 23.80% YTD
+2.10 47.40% 1Y
-2.94 31.05% 3Y
-2.88 30.61% 5Y
+1.25 23.67% 10Y
+5.99 1,109.26% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.15 2.35%

Key metrics

Basic
Market capitalization
$87.9m
Enterprise Value
$78.3m
Net debt
positive
Cash
$9.8m
Shares outstanding
13.8m
Valuation (TTM | estimate)
P/E
19.3 | 28.4
P/S
1.5 | 1.4
EV/Sales
1.4 | 1.3
EV/FCF
11.2
P/B
23.3
Financial Health
Equity Ratio
11.7%
Return on Equity
124.6%
ROCE
57.1%
ROIC
171.6%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$56.9m | $62.2m
EBITDA
$6.5m | $3.1m
EBIT
$4.8m | $-254.0k
Net Income
$4.7m | $3.1m
Free Cash Flow
$7.0m
Growth (TTM | estimate)
Revenue
13.5% | 9.3%
EBITDA
228.5% | -51.6%
EBIT
170.0% | -105.2%
Net Income
164.6% | -34.3%
Free Cash Flow
200.4%
Margin (TTM | estimate)
Gross
50.2%
EBITDA
11.4% | 5.1%
EBIT
8.5%
Net
8.3% | 5.0%
Free Cash Flow
12.3%
More
EPS
$0.3
FCF per Share
$0.5
Short interest
1.9%
Employees
210
Rev per Employee
$270.0k
Show more

Is Champions Oncology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Champions Oncology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Champions Oncology, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Champions Oncology, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Champions Oncology, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Apr '25
+/-
%
57 57
14% 14%
100%
- Direct Costs 28 28
3% 3%
50%
29 29
38% 38%
50%
- Selling and Administrative Expenses 17 17
7% 7%
30%
- Research and Development Expense 6.83 6.83
28% 28%
12%
6.49 6.49
229% 229%
11%
- Depreciation and Amortization 1.64 1.64
12% 12%
3%
EBIT (Operating Income) EBIT 4.85 4.85
170% 170%
9%
Net Profit 4.70 4.70
165% 165%
8%

In millions USD.

Don't miss a Thing! We will send you all news about Champions Oncology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Champions Oncology, Inc. Stock News

Neutral
Seeking Alpha
19 days ago
Champions Oncology (NASDAQ:CSBR ) Q4 2025 Earnings Call July 23, 2025 4:30 PM ET Company Participants David Barry Miller - Chief Financial Officer Ronnie Morris - CEO & Director Conference Call Participants Matthew Gregory Hewitt - Craig-Hallum Capital Group LLC, Research Division Operator Greetings. Welcome to the Champions Oncology Fourth Quarter Fiscal Year 2025 Earnings Call.
Neutral
Accesswire
20 days ago
Total annual revenue growth of 14% HACKENSACK, NJ / ACCESS Newswire / July 23, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2025. Fourth Quarter Financial Highlights: Total revenue of $12.3 million Adjusted EBITDA loss of $1.2 million New data li...
Neutral
Accesswire
23 days ago
HACKENSACK, NJ / ACCESS Newswire / July 21, 2025 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the quarter and year ended April 30, 2025, on Wednesday, July 23, 2025, after market close. The company will host a conference call to discuss the results ...
More Champions Oncology, Inc. News

Company Profile

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Head office United States
CEO Ronnie Morris
Employees 210
Founded 1985
Website championsoncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today